The primary goal of lymphoma treatment is to achieve complete clinical remission while preserving normal tissue function and minimizing acute and long-term toxicity. Therapy is stratified by lymphoma category, primarily Hodgkin lymphoma and Non-Hodgkin lymphoma, and further subdivided into indolent or aggressive diseases according to international standard guidelines.

Treatment begins with comprehensive staging and risk stratification. Chemoimmunotherapy regimens are administered intravenously in repeated cycles, typically every 2 to 3 weeks over 4 to 6 months. Targeted oral agents, bispecific antibodies, CAR T-cell infusions, or radiation therapy are integrated based on specific clinical guidelines.

Evidence-based lymphoma therapies aim to achieve cure or durable disease control, resolve systemic constitutional symptoms, restore normal bone marrow activity, reduce tumor burden, and prolong progression-free and overall survival.

Recovery timelines vary according to protocol intensity, ranging from brief inter-cycle recovery periods during outpatient immunochemotherapy to multi-month hematopoietic and immune reconstitution following autologous stem cell transplantation or CAR T-cell therapy.

Lymphoma treatment addresses lymphatic malignancies including classical Hodgkin lymphoma, nodular lymphocyte-predominant Hodgkin lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, peripheral T-cell lymphomas, and chronic lymphocytic leukemia/small lymphocytic lymphoma.

Pre-treatment evaluation includes tissue biopsy confirmation, baseline fluorine-18 fluorodeoxyglucose positron emission tomography-computed tomography, echocardiography or multigated acquisition scan to assess cardiac function, pulmonary function testing, viral screening, and baseline laboratory studies.

Side effects vary by protocol. Common acute side effects include myelosuppression, fatigue, nausea, alopecia, and mucositis. Serious risks include febrile neutropenia, opportunistic infections, organ toxicity, cytokine release syndrome with cellular therapies, and secondary malignancies.

The treatment journey transitions through diagnostic workup, baseline organ assessment, active therapy administration across structured cycles, response monitoring via functional PET imaging, and structured long-term survivorship surveillance to identify recurrence or late therapeutic effects.